Passage Bio (PASG) Competitors $5.73 -0.05 (-0.87%) Closing price 04:00 PM EasternExtended Trading$6.26 +0.52 (+9.16%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PASG vs. INCR, PMVP, GNTA, QNTM, TELO, CUE, AVTX, IRD, ANEB, and FBRXShould you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include InterCure (INCR), PMV Pharmaceuticals (PMVP), Genenta Science (GNTA), Quantum Biopharma (QNTM), Telomir Pharmaceuticals (TELO), Cue Biopharma (CUE), Avalo Therapeutics (AVTX), Opus Genetics (IRD), Anebulo Pharmaceuticals (ANEB), and Forte Biosciences (FBRX). These companies are all part of the "pharmaceutical products" industry. Passage Bio vs. Its Competitors InterCure PMV Pharmaceuticals Genenta Science Quantum Biopharma Telomir Pharmaceuticals Cue Biopharma Avalo Therapeutics Opus Genetics Anebulo Pharmaceuticals Forte Biosciences InterCure (NASDAQ:INCR) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment. Do analysts prefer INCR or PASG? Passage Bio has a consensus target price of $150.00, suggesting a potential upside of 2,517.80%. Given Passage Bio's stronger consensus rating and higher probable upside, analysts clearly believe Passage Bio is more favorable than InterCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Passage Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is INCR or PASG more profitable? InterCure's return on equity of 0.00% beat Passage Bio's return on equity.Company Net Margins Return on Equity Return on Assets InterCureN/A N/A N/A Passage Bio N/A -93.59%-59.65% Does the media prefer INCR or PASG? In the previous week, Passage Bio had 3 more articles in the media than InterCure. MarketBeat recorded 4 mentions for Passage Bio and 1 mentions for InterCure. InterCure's average media sentiment score of 0.00 equaled Passage Bio'saverage media sentiment score. Company Overall Sentiment InterCure Neutral Passage Bio Neutral Which has higher earnings & valuation, INCR or PASG? InterCure has higher revenue and earnings than Passage Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInterCure$64.55MN/A-$18.32MN/AN/APassage BioN/AN/A-$64.77M-$20.40-0.28 Do institutionals and insiders hold more shares of INCR or PASG? 8.3% of InterCure shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 0.2% of InterCure shares are held by company insiders. Comparatively, 5.0% of Passage Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, INCR or PASG? InterCure has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. SummaryPassage Bio beats InterCure on 7 of the 11 factors compared between the two stocks. Get Passage Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PASG vs. The Competition Export to ExcelMetricPassage BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.03M$3.06B$5.70B$9.48BDividend YieldN/A2.37%4.59%3.99%P/E Ratio-0.2820.7327.9019.95Price / SalesN/A321.07442.18102.66Price / CashN/A43.2336.5558.97Price / Book0.298.308.635.90Net Income-$64.77M-$55.19M$3.24B$258.42M7 Day Performance-0.69%5.07%3.22%1.94%1 Month Performance-18.52%17.61%10.72%12.02%1 Year Performance-65.42%7.03%34.94%20.81% Passage Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PASGPassage Bio2.5637 of 5 stars$5.73-0.9%$150.00+2,517.8%-65.2%$18.03MN/A-0.28130Insider TradeHigh Trading VolumeINCRInterCure0.1747 of 5 stars$1.55+2.0%N/A-41.2%$69.27M$66.28M0.00350PMVPPMV Pharmaceuticals2.4811 of 5 stars$1.34+0.8%$5.50+310.4%-16.1%$69.10MN/A-1.1450Gap UpGNTAGenenta Science1.8536 of 5 stars$3.77-0.1%$25.00+564.0%-14.7%$68.95MN/A0.007QNTMQuantum BiopharmaN/A$23.71+1.5%N/AN/A$67.95MN/A-1.48N/ATELOTelomir Pharmaceuticals2.9585 of 5 stars$2.21-3.1%$15.00+578.7%-48.9%$67.86MN/A-5.261News CoverageHigh Trading VolumeCUECue Biopharma3.5649 of 5 stars$0.88-1.9%$3.00+239.8%+19.9%$67.82M$9.29M-1.3260AVTXAvalo Therapeutics2.7789 of 5 stars$6.73+7.7%$30.00+345.8%-45.9%$67.67M$440K0.0040IRDOpus Genetics1.2055 of 5 stars$1.19+5.3%$7.33+516.2%N/A$67.42M$10.99M-0.5714News CoverageANEBAnebulo Pharmaceuticals2.1832 of 5 stars$1.80+9.8%$5.50+205.6%+38.8%$67.38MN/A-6.924News CoverageAnalyst ForecastGap DownFBRXForte Biosciences3.3161 of 5 stars$10.11-0.7%$61.00+503.4%+46,772.2%$67.02MN/A-0.625Options VolumeGap Up Related Companies and Tools Related Companies INCR Alternatives PMVP Alternatives GNTA Alternatives QNTM Alternatives TELO Alternatives CUE Alternatives AVTX Alternatives IRD Alternatives ANEB Alternatives FBRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PASG) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!99.8% voted YES on this crypto partnership Kraken—one of the world's biggest crypto exchanges—just picked O...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredThe big winner of Crypto week?It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bit...Weiss Ratings | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Passage Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Passage Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PASG Stock Alerts